PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	251-274	fibroblast growth factor 23	Homo sapiens	79-106	
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	251-274	fibroblast growth factor 23	Homo sapiens	108-113	
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	276-285	fibroblast growth factor 23	Homo sapiens	79-106	
34203792-3	2021	Typical biochemical findings include elevated serum levels of bioactive/intact fibroblast growth factor 23 (FGF23) which lead to (i) low serum phosphate levels, (ii) increased fractional excretion of phosphate, and (iii) inappropriately low or normal 1,25-dihydroxyvitamin D (1,25-vitD).	1,25-dihydroxyvitamin D	276-285	fibroblast growth factor 23	Homo sapiens	108-113	
34203792-8	2021	Burosumab binds circulating intact FGF23 and blocks its biological effects in target tissues, resulting in increased serum inorganic phosphate (Pi) concentrations and increased conversion of inactive vitamin D to active 1,25-vitD.	1,25-dihydroxyvitamin D	220-229	fibroblast growth factor 23	Homo sapiens	35-40